Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2020
Polyzos, S. A., & Kountouras J. (2020).  Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.. Ann Hepatol. 19(5), 579-580.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Zavos C., & Doulberis M. (2020).  Erratum to: Letter to the editor re: Li et al. (2020), 'The potential role of bacteria in pancreatic cancer: A systematic review'.. Carcinogenesis.
Kountouras, J., Papaefthymiou A., Gavalas E., Polyzos S. A., Boziki M., Kyriakou P., et al. (2020).  Helicobacter pylori infection as a potential risk factor for multiple sclerosis.. Med Hypotheses. 143, 110135.
Doulberis, M., Papaefthymiou A., Polyzos S. A., Kotronis G., Gialamprinou D., Tzitiridou-Chatzopoulou M., et al. (2020).  Helicobacter pylori, Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. Obes Surg.
Polyzos, S. A., Papaefthymiou A., Doulberis M., Katsinelos P., & Kountouras J. (2020).  Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited.. J Gastrointestin Liver Dis. 29(2), 270-271.
Kountouras, J., Doulberis M., Papaefthymiou A., & Polyzos S. A. (2020).  Impact of Helicobacter pylori-linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk.. Liver Int.
Papaefthymiou, A., Doulberis M., Polyzos S. A., Katsinelos P., Liatsos C., Koffas A., et al. (2020).  Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.. Aliment Pharmacol Ther. 51(2), 313-314.
Papaefthymiou, A., Doulberis M., Polyzos S. A., Katsinelos P., & Kountouras J. (2020).  Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.. Aliment Pharmacol Ther. 51(11), 1215-1216.
Polyzos, S. A., & Mantzoros C. S. (2020).  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).. Metabolism. 154318.
Efstathiadou, Z. A., Kostoulas C., Polyzos S. A., Adamidou F., Georgiou I., & Kita M. (2020).  A mutation in NOTCH2 gene first associated with Hajdu-Cheney syndrome in a Greek family: diversity in phenotype and response to treatment.. Endocrine.
Papaefthymiou, A., Doulberis M., Polyzos S. A., & Kountouras J. (2020).  National consensus on infection: the next-day challenge.. Ann Gastroenterol. 33(3), 324-325.
Polyzos, S. A., Mousiolis A., Mintziori G., & Goulis D. G. (2020).  Nonalcoholic fatty liver disease in males with low testosterone concentrations.. Diabetes Metab Syndr. 14(5), 1571-1577.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2020).  Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.. Metabolism. 104, 154144.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Zavos C., Vagdatli E., et al. (2020).  Potential Impact of Helicobacter pylori Infection on Reflux Disease Sequence: Illuminating the Gap.. J Clin Gastroenterol. 54(2), 200-201.
Boziki, M., Grigoriadis N., Doulberis M., Papaefthymiou A., Polyzos S. A., & Kountouras J. (2020).  Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis.. Dig Liver Dis. 52(1), 121-123.
Anastasilakis, A. D., Trovas G., Balanika A., Polyzos S. A., Makras P., & Tournis S. (2020).  Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.. J Clin Densitom.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Zavos C., & Doulberis M. (2020).  Response to letter to the editor of Carcinogenesis by Li et al., 2020.. Carcinogenesis. 41(4), 539-540.
Doulberis, M., Papaefthymiou A., Polyzos S. A., Katsinelos P., Grigoriadis N., Srivastava D. S., et al. (2020).  Rodent models of obesity.. Minerva Endocrinol. 45(3), 243-263.
Polyzos, S. A., Kountouras J., Goulas A., & Duntas L. (2020).  Selenium and selenoprotein P in nonalcoholic fatty liver disease.. Hormones (Athens). 19(1), 61-72.
Karras, S. N., Koufakis T., Adamidou L., Polyzos S. A., Karalazou P., Thisiadou K., et al. (2020).  Similar late effects of a 7-week orthodox religious fasting and a time restricted eating pattern on anthropometric and metabolic profiles of overweight adults.. Int J Food Sci Nutr. 1-11.
Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. (2020).  The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.. Bone. 138, 115478.
Doulberis, M., Polyzos S. A., Papaefthymiou A., Katsinelos P., Kiosses C., & Kountouras J. (2020).  Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents.. Expert Opin Pharmacother. 21(3), 247-251.
Polyzos, S. A., & Goulas A. (2020).  Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing.. Med Hypotheses. 110379.
Kountouras, J., Gavalas E., Papaefthymiou A., Tsechelidis I., Polyzos S. A., Bor S., et al. (2020).  Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial.. Medicina (Kaunas). 56(7), 
Doulberis, M., Papaefthymiou A., Srivastava D. S., Exadaktylos A. K., Katsinelos P., Kountouras J., et al. (2020).  Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection.. Int J Clin Pract. e13737.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές